-

Simple Contrast Ultrasound Scan Resolves Indeterminate MR and CT

CHICAGO--(BUSINESS WIRE)--A simple, noninvasive contrast enhanced ultrasound (CEUS) scan is an ideal tool for resolving frequent indeterminate MR and CT scans, according to Dr. Stephanie Wilson, a clinical professor of radiology and gastroenterology at the University of Calgary and Co-President of the International Contrast Ultrasound Society.

“CEUS often overcomes limitations of MR and CT in diagnosing many tumors and detecting their recurrence,” said Dr. Wilson, who spoke today at the International Bubble Conference in Chicago.

CEUS uses ultrasound contrast agents comprised of suspensions of tiny injectable “microbubbles” that do not contain dye, create no known risk of kidney damage or deposit of contrast media in the brain, and do not expose patients or hospital staff to ionizing radiation.

In addition, “CEUS scans are significantly less expensive than MR and CT,” she said.

Because the microbubbles stay inside the blood vessels and never go into the tissue, they provide the most accurate blood flow information as compared to interstitial agents used for CT and MR, Dr. Wilson explained. Blood flow assessment is essential for diagnosis and characterization of tumors and detection of recurrences following treatment, she added.

“In addition, in cystic neoplasms anywhere in the body, including the liver, small deposits of tumor are detected on high resolution CEUS with superior sensitivity when compared to MR, which doesn’t even show the nodule or blood flow,” Dr. Wilson said.

“Further, for liver imaging, CEUS overcomes MR limitations associated with fat and iron,” she added.

CEUS is also used to help diagnose heart and vascular disease, monitor chronic gastro-intestinal diseases, evaluate other serious medical conditions and monitor therapy.

Ultrasound contrast agents are currently available worldwide from Bracco, Lantheus and GE Healthcare.

ABOUT ICUS:

The International Contrast Ultrasound Society (ICUS) is a nonprofit medical society dedicated to advancing the safe and medically appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care globally. Membership in ICUS is available free of charge and there is no fee for ICUS CME-accredited educational programs, newsletters or other resources.

To join ICUS and learn more about CEUS, download ICUS Connect and visit the ICUS website (www.icus-society.org).

Contacts

International Contrast Ultrasound Society
Linda Maiman Feinstein, Advisor -- 847-624-1844 or 312-876-2563, Linda.Feinstein@Dentons.com
Robin J. Adams, Director of Communication -- 202-408-3946, Robin.Adams@Dentons.com

International Contrast Ultrasound Society


Release Summary
A simple, noninvasive CEUS scan is an ideal tool for resolving frequent indeterminate MR and CT scans.
Release Versions

Contacts

International Contrast Ultrasound Society
Linda Maiman Feinstein, Advisor -- 847-624-1844 or 312-876-2563, Linda.Feinstein@Dentons.com
Robin J. Adams, Director of Communication -- 202-408-3946, Robin.Adams@Dentons.com

More News From International Contrast Ultrasound Society

CMS Doubles Payment for Contrast-Enhanced Ultrasound Scans

CHICAGO--(BUSINESS WIRE)--Payment for certain contrast-enhanced ultrasound (CEUS) imaging procedures will double under a newly assigned billing code, according to an announcement by the International Contrast Ultrasound Society (ICUS) which advocated for the reimbursement upgrade. The change, published in the Federal Register today and effective January 1, 2026, will increase non-cardiac CEUS reimbursement from $170.02 to $358.35. It also reassigns non-cardiac CEUS to the same billing code used...

Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors

CHICAGO--(BUSINESS WIRE)--Contrast enhanced ultrasound (CEUS) is superior to contrast magnetic resonance (MR) and computed tomography (CT), and offers 100% sensitivity and specificity, for finding residual or recurrent kidney tumors in patients who have had a kidney-sparing procedure, according to a new study announced today at the 39th annual International Bubble Conference in Chicago. The study assessed 193 kidney lesions in 188 patients at two medical centers over approximately six years, ac...

New Studies Show Microbubble Ultrasound Contrast Agents Improve Liver Tumor Response to Radiotherapy and Survival

CHICAGO--(BUSINESS WIRE)--Two new clinical trials show that microbubble ultrasound contrast agents safely and effectively improve liver tumor responses to radiotherapy and patient survival, according to results announced today by Dr. John Eisenbrey, professor of radiology at Thomas Jefferson University, at the 39th annual International Bubble Conference in Chicago. One study found that patients with aggressive intrahepatic cholangiocarcinoma (ICC) and liver metastasis showed a greater than 50%...
Back to Newsroom